Filing Flows › Consumer Staples › Longevity Health Holdings (XAGE)
Longevity Health Holdings (XAGE) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Longevity Health Holdings (XAGE) Q2 2026 earnings results →
Q2 2026 Revenue down 21% year over year to $396K · 476¢ of every $1 of revenue lost · operating margin -182.9%
Longevity Health Holdings made $396K in Q2 2026 (-21% Y/Y). Operating margin -182.9%, net loss $1.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $396K in Q2 2026, down 21% year over year and up 1% from the previous quarter.
Gross margin was 59.5%, down 0.6 points from Q2 2025. Operating costs exceeded revenue by $724K, an operating margin of -182.9%. Operating expenses fell 56% while revenue fell 21%. The quarter ended with a net loss of $1.9M, wider than the previous quarter's $1.4M loss. Net interest and other expense of $1.2M was the main reason.
Operating cash flow was −$224K. Non-cash charges added back $13K of depreciation and amortization and $79K of share-based compensation. Working capital and other items added $1.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $396K | -21% | -182.9% | −$1.9M | −$224K |
| Q1 2026 | 10-Q | May 15, 2026 | $392K | -23% | -339.1% | −$1.4M | −$485K |
| Q4 2025 | 10-K | Mar 31, 2026 | $473K | 27× | -480.2% | −$2.1M | −$306K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $426K | 21× | -345.4% | −$1.4M | −$1.4M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $504K | 41× | -369.1% | −$1.9M | −$836K |
| Q1 2025 | 10-Q | May 15, 2025 | $510K | — | -295.2% | −$1.5M | −$753K |
| Q4 2024 | 10-K | Mar 31, 2025 | $17K | — | n/m | −$914K | −$772K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Longevity Health Holdings
Unless the context requires otherwise, references in this Annual Report on Form 10-K (this “Annual Report”) to the “Company,” “Longevity,” “we,” “us,” or “our,” on or after July 14, 2023 are intended to refer to Longevity Health Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and prior to such date are intended to refer to Carmell Regen Med Corporation (formerly Carmell Therapeutics Corporation), a Delaware corporation, (“Legacy Carmell”). This Annual Report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
In its own words, from its 10-K, filed Mar 31, 2026.
Longevity Health Holdings against its Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -21% against the peers' median +13%. Operating margin: -182.9% against the peers' median 17.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| XAGE Longevity Health Holdings | Q2 2026 | $396K | -21% | -182.9% |
| PG Procter & Gamble | Q1 FY27 | $23.3B | +4% | 25.5% |
| ECL Ecolab | Q3 2026 | $4.7B | +13% | 17.3% |
| CHD Church & Dwight | Q3 2026 | $1.6B | +1% | 18.2% |
| SCL Stepan | Q3 2026 | $692M | +17% | 3.8% |
| ORIB Orion Bliss | Q1 FY27 | $12K | +300% | -32.0% |
Source: Longevity Health Holdings 10-Q on SEC EDGAR · CIK 1842939 · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
13F: who owns XAGE and who is buying
More on XAGE
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results